Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
NWCL has had a bruising October, falling 35% over the past month and another 18% in the past week alone, and the borrow market has taken notice in a striking and somewhat unusual way.
The most eye-catching development this week is the cost to borrow, which jumped sharply to 16.4% on Tuesday from 7.1% the day before. That near-doubling in a single session is the highest reading in the available history, well above the range of 11 to 15% where CTB had been trading since late September. A spike of that speed usually indicates a sudden demand for short exposure, either new positioning or a squeeze on existing borrows, in a name where the lending pool is not deep.
The rest of the lending picture tells a more contradictory story. Availability is currently extremely loose at nearly 3,900%, meaning there are far more shares available to lend than there are existing short positions. That is a dramatic reversal from late September, when availability fell as low as 146%, and it suggests the borrow-cost spike is not being driven by a shortage of supply. The more likely explanation is that the lending market for a small, newly listed UK nuclear technology company trading on Nasdaq remains thin and volatile. Short interest itself is modest at around 808,000 shares, with the most recent FINRA fortnightly figure putting it at roughly 830,000 shares, representing days-to-cover of about 3.2. This is not a heavily shorted stock by any conventional measure.
The ownership data adds important context. The top holders on record are Raffaele Petrone and Stefano Buono, the company's co-founders and key insiders, holding 6.75% and 6.43% of shares respectively as of late September. Beyond those two anchor positions, institutional coverage is thin. The total holder count in the ORTEX data is just six named entities, all with positions reported as of 21 September, which is consistent with a stock that only recently began trading on a US exchange. There are no conventional institutional asset managers visible in the top holders, making the price action harder to attribute to informed portfolio flows.
The earnings history carries one useful data point. A results announcement on 2 October produced a 7.3% one-day gain, which then gave back most of the move, with the stock down 6% over the following five days. That pattern of initial enthusiasm fading suggests the market has found it difficult to anchor a valuation. newcleo is a pre-revenue nuclear technology developer, and no next earnings event is currently scheduled in the ORTEX calendar.
The stock's valuation data is stale, dated to December 2025 and therefore not usable for current analysis. No analyst ratings or price targets are available in the dataset, which is consistent with the company's early-stage listed status and limited sell-side coverage.
What to watch next is whether the CTB spike on Tuesday proves transient, as it did on 9 October when borrow cost briefly spiked before settling, or whether demand for shorts builds at the same time that the share price continues to weaken, a combination that has historically marked the more turbulent phases for lightly covered pre-revenue names.
See the live data behind this article on ORTEX.
Open NWCL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
